Undisclosed GPR35 inhibitor / ThirtyFiveBio - LARVOL DELTA

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program with Initial Focus on Inflammatory Gastrointestinal Disease Ulcerative Colitis (PRNewswire) - "ThirtyFiveBio Limited...announced that the company, along with its long-standing academic collaborator, Nicole Kaneider, Ph.D., of the University of Cambridge, have been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK's innovation agency. The grant, for a total of £643,371 (~$817,000), will fund preclinical research designed to enable the company to pursue a precision medicine approach to patient selection for the clinical development of its first-in-class GPR35 inhibitors. While the company's unique approach to GPR35 inhibition has potential application broadly across GI disease and cancers, ThirtyFiveBio is focusing its initial development activities on inflammatory GI conditions driven by epithelial dysfunction such as ulcerative colitis."

Financing • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023 (PRNewswire) - "ThirtyFiveBio Limited...emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023. The presentation will include a suite of preclinical data highlighting the biological role of GPR35 in GI disease and cancers, outlining the hypothesis that GPR35 activity has the potential to drive pro-oncogenic growth biology in digestive tract cancers, and spotlighting the company's discovery of potent GPR35 inhibitors that demonstrate the ability to prevent GPR35 signaling and tumour growth in a patient-derived cancer model."

Preclinical • Gastrointestinal Cancer • Oncology